Sanofi : Libtayo® (cemiplimab) approuvé dans l’Union européenne pour le traitement du carcinome épidermoïde cutané au stade avancé

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach